Latest news
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary - TradingViewTradingView · Tue, 04 Aug 2026 11:21:01 GMTLarimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver QuantitativeQuiver Quantitative · Tue, 04 Aug 2026 11:15:00 GMTLRMR: Rolling BLA submission for nomlabofusp underway; cash runway into Q3 2027, but more funding needed - TradingViewTradingView · Tue, 04 Aug 2026 11:12:57 GMT